Emerging Celletto Basilard BioTech offers a novel non-viral gene delivery platform Celletto that targets the cell and gene therapies market, presenting a compelling value prop for partners seeking safer, scalable delivery solutions.

Market Differentiation Celletto provides superior transfection efficiency and cell viability in ex vivo applications and enhanced scalability, safety, and cost characteristics in viral delivery, enabling conversations with CGT developers about improving manufacturing yield and reducing lead times.

Funding Readiness With sub-$1M revenue and initial funding of $500K, the company is positioned for early-stage partnerships and co-development opportunities with larger biotech players seeking novel delivery platforms.

Targeted Outreach Focus on cell therapy startups and mid-to-large biopharma pursuing non-viral or hybrid delivery improvements; potential accelerators or incubators in CGT spaces may be interested in pilots or collaboration to de-risk manufacturing scaling.

Strategic Gaps There is a clear need to illustrate how Celletto integrates with existing CGT manufacturing workflows, including regulatory considerations and cost modeling, to convert interest into collaboration and executable pilots.